Cardiomyopathy, Preventive Cardiology, and Quality of
Care/Outcomes. Gregg C. Fonarow, M.D. serves as Director of the
Ahmanson-UCLA Cardiomyopathy Center and is Associate Chief of the
UCLA Division of Cardiology. His research interests center on
heart failure management, cardiomyopathy, preventative cardiology,
outcomes, and implementing systems/disease management to improve
clinical outcomes. Dr. Fonarow has published over 200 research
studies and clinical trials in heart failure management,
preventive cardiology, and quality of care. New therapies and
management strategies for advanced heart failure and research into
the pathophysiology of this disease are conducted at UCLA under
his direction. He is the principle investigator for OPTIMIZE-HF,
IMPROVE-HF, and ADHERE. The UCLA Clinical Practice Guidelines for
heart failure, acute coronary syndromes, and atherosclerosis
prevention and treatment where authored by Dr. Fonarow. He has
also developed and successfully implemented a comprehensive
atherosclerosis treatment program at the UCLA Medical Center
(Cardiac Hospitalization Atherosclerosis Management Program:
CHAMP). He is chair of the steering committee for American Heart
Association Get With The Guidelines Program.
French W, Malmgren J, Parsons L, Sun H. Utilization of lipid
lowering medications at discharge in patients with acute
myocardial infarction: Data from the National Registry of
Myocardial Infarcation 3. Circulation 2001; 103:38-44.
Gawlinski A, Cardin S, Moughrabi S, Tillisch JH. Improved treatment
of cardiovascular disease by implementation of a cardiac
hospitalization atherosclerosis management program: CHAMP. Am J
Cardiol 2001; 87:819-822.
Stevenson LW, Walden JA, Livingston NA, Steimle AE, Hamilton MA,
Moriguchi JD, Tillisch JH, Woo MA. Impact of a comprehensive heart
failure management program on hospital readmission and functional
status of patients with advanced heart failure. J Am Coll Cardiol
Wiener I, Feliciano Z, Knight L, Woo MA, Moriguchi JD, Boyle N, Laks
H Improved survival in patients with nonischemic advanced heart
failure and syncope treated with an implantable defibrillator. Am J
Cardiol, 2000, 85:981-85.
Ballantyne CM. In-hospital initiation of lipid lowering therapy for
patients with coronary heart disease: the time is now. Circulation
Horwich TB, MacLellan
WR, Fonarow GC. Statin therapy is associated with improved
survival in ischemic and non-ischemic heart failure. J Am Coll
Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ; ADHERE Scientific
Advisory Committee, Study Group, and Investigators. Risk
stratification for in-hospital mortality in acutely decompensated
heart failure: classification and regression tree analysis. JAMA.
Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH,
O'Connor CM, Pieper K, Sun JL, Yancy C. Young, JB. Association
Between Performance Measures and Clinical Outcomes for Patients
Hospitalized With Heart Failure. JAMA. 2007;297:61-70.
Abraham WT, Albert NM, Gattis Stough W, Gheorghiade M, Greenberg BH,
O'Connor CM, Pieper K, Sun JL, Yancy CW, Young JB; for the OPTIMIZE-HF
Investigators and Hospitals. Influence of a Performance-Improvement
Initiative on Quality of Care for Patients Hospitalized With Heart
Failure: Results of the Organized Program to Initiate Lifesaving
Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF).
Arch Intern Med. 2007;167:1493-502.